Jump to main content
Jump to site search


Protective effects of astragaloside IV against hypoxic pulmonary hypertension

Author affiliations

Abstract

The present study aimed to evaluate the protective effects of astragaloside IV (As-IV) against hypoxic pulmonary hypertension (HPH) and its mechanisms of action. Sprague-Dawley rats were used in a model of HPH induced by chronic hypoxia. After hypoxia, the mean pulmonary arterial pressure (mPAP), right ventricular pressure (RVP), and right ventricular hypertrophy index (RVHI) were monitored. Relaxation of the pulmonary artery in response to As-IV was measured. The levels of endothelin-1 (ET-1), angiotensin II (Ang II), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in serum were assessed. Cell proliferation was detected by the cell counting kit-8 (CCK-8) assay. Treatment with As-IV significantly decreased mPAP, RVP and RV/(LV + S) and attenuated the development of HPH. Moreover, As-IV time-dependently relaxed the pulmonary arteries from HPH rats. In addition, As-IV decreased the levels of ET-1, Ang II, TNF-α, and IL-6 in serum of HPH rats. In vitro experiments demonstrated that As-IV also significantly inhibited the proliferation of pulmonary artery smooth muscle cells (PASMCs) subjected to hypoxia. Our findings suggested the therapeutic potential of As-IV in the treatment of pulmonary hypertension.

Graphical abstract: Protective effects of astragaloside IV against hypoxic pulmonary hypertension

Back to tab navigation

Publication details

The article was received on 08 Jul 2018, accepted on 29 Aug 2018 and first published on 04 Sep 2018


Article type: Research Article
DOI: 10.1039/C8MD00341F
Citation: Med. Chem. Commun., 2018, Advance Article
  •   Request permissions

    Protective effects of astragaloside IV against hypoxic pulmonary hypertension

    X. Zhang, J. Chen, P. Xu and X. Tian, Med. Chem. Commun., 2018, Advance Article , DOI: 10.1039/C8MD00341F

Search articles by author

Spotlight

Advertisements